RECRUITINGINTERVENTIONAL
Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver
About This Trial
The purpose of this study is to quantitatively assess the changes in liver fat content in cancer patients before and after treatment. The main questions it aims to answer are:How does the liver fat fraction change before and after chemotherapy? In this study, patients undergoing mDixon Quant scanning are subjected to fully automated segmentation and measurement of liver fat content using artificial intelligence.
Who May Be Eligible (Plain English)
Who May Qualify:
1. CT/B ultrasound showed no fatty liver
2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia
3. Received neoadjuvant/adjuvant chemotherapy
Who Should NOT Join This Trial:
1. Missing follow-up information
2. Liver lesions (metastases, hemangioma, etc.)
3. Poor image quality
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. CT/B ultrasound showed no fatty liver
2. No MRI contraindications, including pacemaker, stent, metal implant, or claustrophobia
3. Received neoadjuvant/adjuvant chemotherapy
Exclusion Criteria:
1. Missing follow-up information
2. Liver lesions (metastases, hemangioma, etc.)
3. Poor image quality
Treatments Being Tested
DRUG
Neoadjuvant chemotherapy
Neoadjuvant chemotherapy
Locations (1)
Yunnan Cancer Hospital
Kunming, Yunnan, China